Al-Fadel Nouf, Mahmoud Mansour A, Dabliz Rabih, Tabbara Osama, Aljadhey Hisham
Vigilance and Benefit-Risk Assessment Executive Directorate, Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
Medication Safety Research Chair, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Eur J Hosp Pharm. 2016 Nov;23(6):339-342. doi: 10.1136/ejhpharm-2015-000872. Epub 2016 Mar 21.
To evaluate implementation of safety standards of compounded sterile preparations in different hospitals.
This cross-sectional study included 124 hospitals from 19 countries. A survey was developed based on the guidelines and safety practices of the Institute for Safe Medication Practices (ISMP) for sterile preparations compounding, and was sent to the members of the Intravenous and Parenteral Nutrition experts' network (IV PN experts' network) in the Gulf region and beyond using SurveyMonkey software.
124 pharmacists were invited to participate in this study. Only 39 (31.5%) pharmacists from seven countries responded: 16 (41%) of the participants were pharmacy supervisors, and 23 (59%) had >10 years of work experience. However, a majority, 27 (69%), of the respondents were from Saudi Arabia. Written policies and procedures for sterile preparations compounding were available in 37 (95%) hospitals. The concentrated electrolytes were removed from all patient care areas in 28 (72%) hospitals, and 30 (77%) hospitals clearly labelled those as high-alert medications. The use of advanced technologies, such as bar code verification or IV robotics, for compounding sterile preparations were not implemented in 27 (69%) hospitals.
Minimum standards and best practice recommendations to ensure safety of sterile preparation compounding were implemented in many hospitals of different countries. However, advanced technologies were not implemented by the majority of the hospitals.
评估不同医院中无菌配制制剂安全标准的实施情况。
这项横断面研究纳入了来自19个国家的124家医院。根据安全用药实践研究所（ISMP）关于无菌制剂配制的指南和安全规范制定了一项调查，并通过SurveyMonkey软件发送给海湾地区及其他地区的静脉和肠外营养专家网络（IV PN专家网络）的成员。
邀请了124名药剂师参与本研究。只有来自7个国家的39名（31.5%）药剂师做出了回应：16名（41%）参与者是药房主管，23名（59%）有超过10年的工作经验。然而，大多数（69%）受访者来自沙特阿拉伯。37家（95%）医院有关于无菌制剂配制的书面政策和程序。28家（72%）医院在所有患者护理区域移除了浓缩电解质，30家（77%）医院将其明确标记为高警示药品。27家（69%）医院未采用如条形码验证或静脉用药机器人等先进技术进行无菌制剂配制。
不同国家的许多医院实施了确保无菌制剂配制安全的最低标准和最佳实践建议。然而，大多数医院未采用先进技术。
